- Evolokumab in the treatment of dyslipidemia, focusing on familial hypercholesterolemia2015 | First Faculty of Medicine
- Evolokumab for the treatment of familial hypercholesterolaemia2017 | Faculty of Medicine in Hradec Králové
- What have imaging studies with evolocumab yielded?2022 | First Faculty of Medicine
- Evolocumab and PROFICIO Project: Initial Results2015 | Third Faculty of Medicine
- Evolokumab v léčbě dyslipidemií se zaměřením na familiární hypercholesterolemii2016 | First Faculty of Medicine
- PCSK9 inhibitor evolocumab in the FOURIER outcomes trial2017 | First Faculty of Medicine
- Evolocumab for the treatment of familial hypercholesterolemia2017 | Faculty of Medicine in Hradec Králové
- Anti-PCSK9 - evolokumab2015 | Third Faculty of Medicine
- Komentář ke studii Glagov2017 | First Faculty of Medicine
- Evolocumab: lowering of both the LDL cholesterol and cardiovascular risk2015 | First Faculty of Medicine
- Evolocumab - antibody against PCSK9 with a profound lipid-lowering effect2015 | First Faculty of Medicine
- Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?2017 | First Faculty of Medicine
- Biologická léčba hypercholesterolemie2017 | First Faculty of Medicine
- The role of PCSK9-inhibitors and of lipoprotein apheresis in the treatment of homozygous and severe heterozygous familial hypercholesterolemia: A rivalry, or are things quite different?2018 | Faculty of Medicine in Hradec Králové
- Comments on the most important and recent studies involving PCSK9i2018 | First Faculty of Medicine
- Lipoprotein(a) - the cardiovascular risk factor: significance and therapeutic possibilities2018 | Faculty of Medicine in Hradec Králové
- Position of lipoprotein apheresis in present2015 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Proprotein convertase subtilisin/kexin type 9 inhibitors in the treatment of a patient with dyslipidemia and myopathy2019 | Third Faculty of Medicine
- Aktuality ze světa inhibice PCSK92019 | First Faculty of Medicine
- Monoklonální protilátky v preventivní kardiologii2016 | First Faculty of Medicine
- PCSK-inhibitor in theory, in studies and in the real practice2019 | First Faculty of Medicine
- Examination methods for coronary atherosclerosis regression with special focus on GLAGOV trial2018 | First Faculty of Medicine
- Nová hypolipidemika a jejich vliv na cévní stěnu a kardiovaskulární riziko2017 | Faculty of Medicine in Pilsen
- Therapy with drugs containing the active ingredient LOMITAPIDE in patients with homozygous form of familial hypercholesterolemia: a statement of the committee of the Czech Society for Atherosclerosis2020 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated? Czech atherosclerosis society statement2016 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- An initiative to establish apheresis centers: indications for and performance of lipoprotein apheresis in the Czech Republic2019 | First Faculty of Medicine, Faculty of Medicine in Hradec Králové, Second Faculty of Medicine
- Nedostatečná korekce hodnot LDL cholesterolu u nemocných s periferní aterosklerózou: jak zlepšit tento stav?2022 | First Faculty of Medicine, Third Faculty of Medicine
